Which has the lower trailing P/E, CAH or TEVA?

CAH has the lower trailing P/E: CAH trades at 33.95 and TEVA at 62.48. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, CAH or TEVA?

Over the past five years, CAH grew revenue faster — CAH at a 9.37% CAGR versus TEVA at 1.19%.

Does CAH or TEVA pay a bigger dividend?

CAH pays a dividend (0.83% yield), while TEVA is a former payer with no current dividend run rate.

Is CAH or TEVA more profitable?

TEVA runs the higher net margin — CAH at 0.67% versus TEVA at 4.08%.

How have CAH and TEVA total returns compared?

Over the past 10 years, CAH delivered 15.06% and TEVA delivered -2.67% annualized total return. Past performance doesn't predict future results.

Cardinal Health, Inc. (CAH) vs Teva Pharmaceutical Industries Limited (TEVA)

A side-by-side comparison of Cardinal Health, Inc. and Teva Pharmaceutical Industries Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 3, 2026. Differences are shown without an overall score or investment verdict.

CAH

Cardinal Health, Inc.

$58.22B

$248.57HealthcareDelayed quote: Sep 3, 2026, 3:59 PM EDT

TEVA

Teva Pharmaceutical Industries Limited

$42.64B

$36.61HealthcareDelayed quote: Sep 3, 2026, 3:59 PM EDT

Total return — CAH vs TEVA

growth of $100 · dividends reinvested · last 10y

CAH +305.4% (+15.0%/yr)TEVA -24.2% (-2.7%/yr)CAH compounded faster over this window

Log scale — wide-divergence pair

CAH TEVA

CAH vs TEVA: by the numbers

•CAH is the larger company ($58.22B vs $42.64B market cap).
•CAH trades at the lower trailing earnings multiple (33.95 vs 62.48 P/E), one valuation lens rather than an overall verdict.
•TEVA converts more revenue to profit (4.08% vs 0.67% net margin).
•CAH grew revenue faster over the past five years (9.37% vs 1.19% CAGR).
•CAH pays a dividend (0.83% yield), while TEVA is a former payer with no current dividend run rate.

Metrics side by side

Valuation

Metric	CAH	TEVA
P/E ratio	33.95	62.48
Forward P/E	22.78	18.74
P/S ratio	0.23	2.56
P/B ratio	N/A	5.71
EV / EBITDA	17.73	19.35
FCF yield	7.78%	3.04%

Profitability

Metric	CAH	TEVA
Gross margin	3.84%	52.47%
Operating margin	1.03%	11.45%
Net margin	0.67%	4.08%
ROE	-59.45%	9.10%
ROIC	13.45%	6.79%

Dividends

Metric	CAH	TEVA
Dividend yield	0.83%	N/A
Payout ratio	28.17%	N/A

Growth (annualized)

Metric	CAH	TEVA
Revenue CAGR (5Y)	9.37%	1.19%
EPS CAGR (5Y)	28.32%	N/A
FCF CAGR (5Y)	17.40%	14.58%
Total return CAGR (5Y)	38.59%	31.54%

Frequently asked

Which has the lower trailing P/E, CAH or TEVA?: CAH has the lower trailing P/E: CAH trades at 33.95 and TEVA at 62.48. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, CAH or TEVA?: Over the past five years, CAH grew revenue faster — CAH at a 9.37% CAGR versus TEVA at 1.19%.
Does CAH or TEVA pay a bigger dividend?: CAH pays a dividend (0.83% yield), while TEVA is a former payer with no current dividend run rate.
Is CAH or TEVA more profitable?: TEVA runs the higher net margin — CAH at 0.67% versus TEVA at 4.08%.
How have CAH and TEVA total returns compared?: Over the past 10 years, CAH delivered 15.06% and TEVA delivered -2.67% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CAH analysis Full TEVA analysis Interactive comparison tool

Dig into the metrics

Cardinal Health P/E ratio Teva Pharmaceutical Industries P/E ratio Cardinal Health dividend yield Cardinal Health ROE Teva Pharmaceutical Industries ROE Cardinal Health operating margin Teva Pharmaceutical Industries operating margin Cardinal Health revenue growth Teva Pharmaceutical Industries revenue growth Cardinal Health free cash flow Teva Pharmaceutical Industries free cash flow

Cardinal Health & Teva Pharmaceutical Industries appear in these rankings

25+ Year Dividend Growers Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 3, 2026.